A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT06311721. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this trial is to demonstrate pharmacokinetic (PK) similarity of ABP 234 compared with the pembrolizumab reference product (Keytruda®).
Study identification
- NCT ID
- NCT06311721
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 315 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 9, 2024 (Actual)
- Primary completion
- Jan 10, 2028 (Estimated)
- Completion
- Apr 24, 2028 (Estimated)
- Last update posted
- May 6, 2026
2024 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Precision NextGen Oncology and Research Center | Beverly Hills | California | 90212 | — |
| TOI Clinical Research | Cerritos | California | 90703 | — |
| Cancer and Blood Specialty Clinic (CBSC) | Los Alamitos | California | 90720-3309 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| PIH Health Hospital | Whittier | California | 90602 | — |
| Millennium Oncology - Hollywood | Hollywood | Florida | 33024 | — |
| BRCR Medical Center Inc. | Tamarac | Florida | 33321 | — |
| Accellacare Duly | Plainfield | Illinois | 60585 | — |
| Accellacare of McFarland | Ames | Iowa | 50010 | — |
| Detroit Clinical Research Center, PC | Farmington Hills | Michigan | 48334 | — |
| North Shore Hematology-Oncology Associates P.C. d/b/a New York Cancer & Blood Specialists | Shirley | New York | 11967 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Millennium Research and Clinical Development, LLC | Houston | Texas | 77090 | — |
| Texas Oncology, P.A | San Antonio | Texas | 78217 | — |
| Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care | Wytheville | Virginia | 24382 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 203 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06311721, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06311721 live on ClinicalTrials.gov.